ASCO26: AstraZeneca unveils data it hopes will persuade FDA to approve oral SERD on June 03, 2026 Approved ASCO26 AstraZeneca camizestrant Clearance ctDNA ESR1 gene HR+ Malignant neoplasm of breast Mutation Oncologic Drugs Advisory Committee oral SERD SERENA-6 trial United States Food and Drug Administration +
Roche's Oral SERD Giredestrant Shows Mixed Clinical Results but Remains Strategically Important on April 23, 2026 Clinical Trials early-stage lidERA Malignant neoplasm of breast oral SERD Roche (company) +
Roche's Oral SERD Giredestrant Fails Phase 3 persevERA Trial in First-Line Breast Cancer on March 11, 2026 giredestrant Malignant neoplasm of breast oral SERD persevERA PFS Roche (company) +
Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial on December 11, 2025 Adjuvant Therapy ER-positive giredestrant HER2-negative hormone receptor-positive Hormone Therapy Malignant neoplasm of breast oral SERD Recurrence Risk Roche (company) +
Roche's Oral SERD Giredestrant Delays Early Breast Cancer Recurrence in Late-Stage Trial on November 18, 2025 Adjuvant Therapy Disease-Free Survival ER-positive giredestrant HER2-negative Malignant neoplasm of breast oral SERD Phase 3 trial recurrence prevention Roche (company) +
Roche's Giredestrant Advances Oral SERD Debate at ESMO 2025 on October 21, 2025 ER-Positive HER2-Negative Breast Cancer ESMO giredestrant oral SERD Roche (company) +
Roche Claims Its SERD Is Most Potent After Positive Breast Cancer Data Presented at ESMO 2025 on October 20, 2025 ER-positive giredestrant HER2-negative Malignant neoplasm of breast oral SERD Phase 3 Trial Progression-Free Survival Roche (company) Selective Estrogen Receptor Down Regulator +
Eli Lilly's Oral SERD Inluriyo Approved by FDA for ESR1-Mutated Breast Cancer on September 26, 2025 Approved Carcinoma breast stage IV Eli Eli Lilly EMBER-3 trial ESR1 gene Estrogen receptor positive HER2-negative Imlunestrant Inluriyo Mutation oral SERD United States Food and Drug Administration +
Roche's Oral SERD Achieves Progression-Free Survival Milestone in Pivotal Breast Cancer Trial on September 23, 2025 advanced breast cancer Clinical Research ER-positive giredestrant Hormone Therapy Malignant neoplasm of breast oral SERD Phase 3 Clinical Trials Progression-Free Survival Roche (company) +
AstraZeneca Details Its Oral SERD 'Switching' Regimen Amid Feasibility Questions on June 01, 2025 AstraZeneca camizestrant CDK4/6 inhibitor Disease Progression ESR1 gene Malignant neoplasm of breast Mutation oral SERD SERENA-6 trial treatment resistance +